Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcriptional Inactivation of TP53 and BMP Pathway Components Mediates Therapy-induced Dedifferentiation and Metastasis in Prostate Cancer

ABSTRACT: This SuperSeries is composed of the SubSeries listed below.

ORGANISM(S): Homo sapiens

PROVIDER: GSE162294 | GEO | 2022/01/20

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Transcriptional Inactivation of TP53 and BMP Pathway Components Mediates Therapy-induced Dedifferentiation and Metastasis in Prostate Cancer (ChIP-seq)

Project description:AR blockade instigates two separate and complementary processes: 1) transcriptional silencing of TP53 and hence acquisition of hybrid E/M and stem-like traits; and 2) inhibition of the BMP signaling, which promotes resistance to the pro-apoptotic and anti-proliferative effects of AR inhibition. The drug tolerant prostate cancer cells generated through reprogramming are rescued by neuregulin and generate metastases in mice.

2022-01-20 | GSE162293 | GEO

Transcriptional Inactivation of TP53 and BMP Pathway Components Mediates Therapy-induced Dedifferentiation and Metastasis in Prostate Cancer (ATAC-seq)

2022-01-20 | GSE162227 | GEO

Transcriptional Inactivation of TP53 and BMP Pathway Components Mediates Therapy-induced Dedifferentiation and Metastasis in Prostate Cancer (RNA-seq)

2022-01-20 | GSE162225 | GEO

Transcriptional Inactivation of TP53 and BMP Pathway Components Mediates Therapy-induced Dedifferentiation and Metastasis in Prostate Cancer

Project description:Transcriptional Inactivation of TP53 and BMP Pathway Components Mediates Therapy-induced Dedifferentiation and Metastasis in Prostate Cancer

| PRJNA681284 | ENA

Transcriptional Inactivation of TP53 and BMP Pathway Components Mediates Therapy-induced Dedifferentiation and Metastasis in Prostate Cancer (RNA-seq)

Project description:Transcriptional Inactivation of TP53 and BMP Pathway Components Mediates Therapy-induced Dedifferentiation and Metastasis in Prostate Cancer (RNA-seq)

| PRJNA681148 | ENA

Transcriptional Inactivation of TP53 and BMP Pathway Components Mediates Therapy-induced Dedifferentiation and Metastasis in Prostate Cancer (ATAC-seq)

Project description:Transcriptional Inactivation of TP53 and BMP Pathway Components Mediates Therapy-induced Dedifferentiation and Metastasis in Prostate Cancer (ATAC-seq)

| PRJNA681153 | ENA

Transcriptional Inactivation of TP53 and BMP Pathway Components Mediates Therapy-induced Dedifferentiation and Metastasis in Prostate Cancer (ChIP-seq)

Project description:Transcriptional Inactivation of TP53 and BMP Pathway Components Mediates Therapy-induced Dedifferentiation and Metastasis in Prostate Cancer (ChIP-seq)

| PRJNA681285 | ENA

Characterization of Hippo Pathway Components by Gene Inactivation.

Project description:The Hippo pathway is important for regulating tissue homeostasis, and its dysregulation has been implicated in human cancer. However, it is not well understood how the Hippo pathway becomes dysregulated because few mutations in core Hippo pathway components have been identified. Therefore, much work in the Hippo field has focused on identifying upstream regulators, and a complex Hippo interactome has been identified. Nevertheless, it is not always clear which components are the most physiologically relevant in regulating YAP/TAZ. To provide an overview of important Hippo pathway components, we created knockout cell lines for many of these components and compared their relative contributions to YAP/TAZ regulation in response to a wide range of physiological signals. By this approach, we provide an overview of the functional importance of many Hippo pathway components and demonstrate NF2 and RHOA as important regulators of YAP/TAZ and TAOK1/3 as direct kinases for LATS1/2.

| S-EPMC5137798 | biostudies-literature

Dedifferentiation by adenovirus E1A due to inactivation of Hippo pathway effectors YAP and TAZ.

Project description:Adenovirus transformed cells have a dedifferentiated phenotype. Eliminating E1A in transformed human embryonic kidney cells derepressed ∼2600 genes, generating a gene expression profile closely resembling mesenchymal stem cells (MSCs). This was associated with a dramatic change in cell morphology from one with scant cytoplasm and a globular nucleus to one with increased cytoplasm, extensive actin stress fibers, and actomyosin-dependent flattening against the substratum. E1A-induced hypoacetylation at histone H3 Lys27 and Lys18 (H3K27/18) was reversed. Most of the increase in H3K27/18ac was in enhancers near TEAD transcription factors bound by Hippo signaling-regulated coactivators YAP and TAZ. E1A causes YAP/TAZ cytoplasmic sequestration. After eliminating E1A, YAP/TAZ were transported into nuclei, where they associated with poised enhancers with DNA-bound TEAD4 and H3K4me1. This activation of YAP/TAZ required RHO family GTPase signaling and caused histone acetylation by p300/CBP, chromatin remodeling, and cohesin loading to establish MSC-associated enhancers and then superenhancers. Consistent results were also observed in primary rat embryo kidney cells, human fibroblasts, and human respiratory tract epithelial cells. These results together with earlier studies suggest that YAP/TAZ function in a developmental checkpoint controlled by signaling from the actin cytoskeleton that prevents differentiation of a progenitor cell until it is in the correct cellular and tissue environment.

| S-EPMC6601516 | biostudies-literature

WFDC2 suppresses prostate cancer metastasis by modulating EGFR signaling inactivation.

Project description:WAP four-disulfide core domain 2 (WFDC2) is a small secretory protein that has been widely studied in ovarian cancer. It has been proven that WFDC2 promotes proliferation and metastasis in ovarian cancer, and serves as a diagnostic biomarker. However, the specific function of WFDC2 in prostate cancer has not been reported. Here, we first screened the diagnostic marker and favorable prognostic factor WFDC2 in prostate cancer by bioinformatics. WFDC2 expression was negatively correlated with Gleason score and metastasis in prostate cancer. Then, we revealed that overexpression of WFDC2, and addition of recombinant protein HE4 can significantly inhibit prostate cancer metastasis in vivo and in vitro. By co-immunoprecipitation and co-localization assays, we proved that WFDC2 binds to the extracellular domain of epidermal growth factor receptor (EGFR). Immunoblot showed that WFDC2 overexpression and recombinant protein HE4 addition inactivated the EGFR/AKT/GSK3B/Snail signaling pathway, and then restrained the progression of epithelial-mesenchymal transition. In conclusion, our study identified that the tumor suppressor WFDC2 can suppress prostate cancer metastasis by inactivating EGFR signaling.

| S-EPMC7366654 | biostudies-literature

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data